Consensus statement: Cardiovascular safety profile of triptans (5-HT 1B/1D agonists) in the acute treatment of migraine

David Dodick, Richard B. Lipton, Vincent Martin, Vasilios Papademetriou, Wayne Rosamond, Antoinette Maassen VanDenBrink, Hassan Loutfi, K. Michael Welch, Peter J. Goadsby, Steven Hahn, Susan Hutchinson, David Matchar, Stephen Silberstein, Timothy R. Smith, R. Allan Purdy, Jane Saiers

Research output: Contribution to journalReview article

234 Scopus citations

Abstract

Background. - Health care providers frequently cite concerns about cardiovascular safety of the triptans as a barrier to their use. In 2002, the American Headache Society convened the Triptan Cardiovascular Safety Expert Panel to evaluate the evidence on triptan-associated cardiovascular risk and to formulate consensus recommendations for making informed decisions for their use in patients with migraine. Objective. - To summarize the evidence reviewed by the Triptan Cardiovascular Safety Expert Panel and their recommendations for the use of triptans in clinical practice. Participants. - The Triptan Cardiovascular Safety Expert Panel was composed of a multidisciplinary group of experts in neurology, primary care, cardiology, pharmacology, women's health, and epidemiology. Evidence and Consensus Process. - An exhaustive search of the relevant published literature was reviewed by each panel member in preparation for an open roundtable meeting. Pertinent issues (eg, cardiovascular pharmacology of triptans, epidemiology of cardiovascular disease, cardiovascular risk assessment, migraine) were presented as a prelude to group discussion and formulation of consensus conclusions and recommendations. Follow-up meetings were held by telephone. Conclusions. - (1) Most of the data on triptans are derived from patients without known coronary artery disease. (2) Chest symptoms occurring during use of triptans are generally nonserious and are not explained by ischemia. (3) The incidence of serious cardiovascular events with triptans in both clinical trials and clinical practice appears to be extremely low. (4) The cardiovascular risk-benefit profile of triptans favors their use in the absence of contraindications.

Original languageEnglish (US)
Pages (from-to)414-425
Number of pages12
JournalHeadache
Volume44
Issue number5
DOIs
StatePublished - May 1 2004

Keywords

  • Consensus statement
  • Headache
  • Migraine
  • Triptans

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Consensus statement: Cardiovascular safety profile of triptans (5-HT <sub>1B/1D</sub> agonists) in the acute treatment of migraine'. Together they form a unique fingerprint.

  • Cite this

    Dodick, D., Lipton, R. B., Martin, V., Papademetriou, V., Rosamond, W., VanDenBrink, A. M., Loutfi, H., Welch, K. M., Goadsby, P. J., Hahn, S., Hutchinson, S., Matchar, D., Silberstein, S., Smith, T. R., Purdy, R. A., & Saiers, J. (2004). Consensus statement: Cardiovascular safety profile of triptans (5-HT 1B/1D agonists) in the acute treatment of migraine. Headache, 44(5), 414-425. https://doi.org/10.1111/j.1526-4610.2004.04078.x